ReNeuron

Focus: ReNeuron is a UK-based stem cell therapy biotech focused on regenerative medicine for neurological and vascular diseases. The company operates as a private pre-revenue entity with a pipeline spanning retinal, stroke, and peripheral arterial disease indications.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 1w ago

Funding Stage

PRIVATE

Open Jobs

About ReNeuron

AI assessmentNot Hiring

No open roles listed right now. Follow ReNeuron to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

8 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Observational Study of Ischaemic Stroke

Stroke

N/A

Clinical Trials (1)

NCT01859572Observational Study of Ischaemic Stroke

N/A

Help build intelligence for ReNeuron

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape early-stage cell therapy platform with multiple shots on goal across three disease areas (retinal, stroke, PAD)
UK-based operation provides access to European regulatory pathways and NHS clinical trial infrastructure
Deep pipeline of 8 active programs (3 Phase 1, 3 Phase 2) in emerging therapeutic modality with high scientific interest

Watch Out For

Private status with undisclosed funding creates cash burn and runway uncertainty; no clear path to liquidity event announced
Zero active job openings currently listed suggests possible hiring freeze or lean organizational structure
No marketed products or revenue generation means all compensation is equity-dependent with unproven exit timeline

Generated by Claude from ReNeuron's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Non Interventional long term safety follow up

Ischemic Stroke

N/A

Clinical Trials (1)

NCT05598775Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

N/A

An Ischaemic Stroke Observational Study

Stroke

N/A

Clinical Trials (1)

NCT03333980An Ischaemic Stroke Observational Study

N/A